Vue transversale de la maladie
Myopathies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
1012 résultats correspondants
· 46 visibles sur cette page
dans le périmètre Myopathies
Niveau clinique
Études et traitements 421
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Semaglutide (Rybelsus®) NCT07642635 · Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individ… | Myopathies | Traitement symptomatique | Phase 1/2 | NOT_YET_RECRUITING | Duchenne Muscular Dystrophy (DMD) is a rare, genetic disease that leads to… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:44 | Détail |
| Skeletal muscle biopsy (residual specimen) NCT06101940 · Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (… | Myopathies | Ralentissement de la progression | À vérifier | ENROLLING_BY_INVITATION | Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disor… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:44 | Détail |
| TODDLER — A Remote Study Using Technology to Assess Outcomes in DMD NCT07423026 · NCT07423026 | Myopathies | À vérifier | À vérifier | RECRUITING | Every year, 100 boys are born in the UK with a rare muscle disease called… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:44 | Détail |
| Adult and Juvenile Myositis NCT00017914 · NCT00017914 | Myopathies | Ralentissement de la progression · Immunomodulation · Traitement symptomatique… | À vérifier | RECRUITING | This study will evaluate subjects with adult- and childhood-onset myositis… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| Botulinum toxin type A NCT05720065 · Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A | Myopathies | Traitement symptomatique | Phase 2 | RECRUITING | The main purpose of this study is to determine which is the best dose of a… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| CovExc — Muscular Rehabilitation by Eccentric Exercise After Severe C… NCT04649086 · NCT04649086 | Myopathies | À vérifier | Non applicable | TERMINATED | With the COVID-19 pandemic, the number of patients to be treated in rehabi… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| Effectiveness of Conservative Interventions in the Treatment of Trigg… NCT06296017 · NCT06296017 | Myopathies | À vérifier | Non applicable | RECRUITING | There is no study in the literature comparing the effectiveness of ESWT an… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| Electrophysiological measurement of reflex nociceptive flexion thresh… NCT04624581 · FIbromyalgia anD GenetIcs Subgroups (FIDGIS) | Myopathies | Traitement symptomatique | Non applicable | COMPLETED | Fibromyalgia syndrome (FS) is characterized by widespread pain and affect… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| Fascial Distortion Model NCT06627855 · Effectiveness of the Fascial Distortion Model in Temporomandibular Disorders: A… | Myopathies | Ralentissement de la progression · Traitement symptomatique | Non applicable | RECRUITING | The aim of the study was to investigate the effectiveness of Manual Therap… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| Intravenously administered pooled human immunoglobulin (IVIG) NCT06599697 · The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Med… | Myopathies | À vérifier | Phase 2 | RECRUITING | This is a randomized, placebo-controlled, double blinded phase 2 explorato… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| LOLA — Effectiveness of Health Education Program on Musculoskeletal P… NCT07160478 · NCT07160478 | Myopathies | Traitement symptomatique | Non applicable | COMPLETED | Musculoskeletal pain during childhood can negatively affect school attenda… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| Prospective, Longitudinal, Observational Registry of Adult Patients W… NCT05596539 · NCT05596539 | Myopathies | À vérifier | À vérifier | RECRUITING | The purpose of this study is to assess medical events during follow-up of… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| Real radial extracorporeal shock wave therapy (rESWT) NCT07476690 · CP-rESWT-FREQ — Effect of rESWT Session Frequency on Spasticity and Function Ass… | Myopathies | Traitement symptomatique | Non applicable | COMPLETED | Spasticity is a major contributor to functional limitations in children wi… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| SeMAFor — Magnesium, Stress and Fibromyalgia NCT03887000 · NCT03887000 | Myopathies | Traitement symptomatique | Non applicable | COMPLETED | Fibromyalgia affects an average of 2% of the French population. Data from… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:43 | Détail |
| AZD5492 NCT06916806 · TITAN — A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharm… | Lupus | Immunomodulation | Phase 1 | RECRUITING | The purpose of this study is to measure the safety, tolerability, PK, and… À vérifier | ClinicalTrials.gov 2026-08-16 21:21:41 | Détail |
| AOC 1020 NCT05747924 · FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral… | Myopathies | À vérifier | Phase 1/2 | COMPLETED | A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluat… À vérifier | ClinicalTrials.gov 2026-08-16 19:04:32 | Détail |
| BMN 351 NCT06280209 · A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Phar… | Myopathies | À vérifier | Phase 1/2 | ACTIVE_NOT_RECRUITING | This open-label extension study aims to evaluate the long-term safety and… À vérifier | ClinicalTrials.gov 2026-08-16 19:04:32 | Détail |
| EPI-321 NCT06907875 · FSHD — A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrop… | Myopathies | Thérapie génique | Phase 1/2 | ACTIVE_NOT_RECRUITING | The goal of this clinical trial is to learn how safe and tolerable EPI-321… À vérifier | ClinicalTrials.gov 2026-08-16 19:04:32 | Détail |
| GNR-097 NCT07673809 · A Study to Evaluate the Tolerability, Safety and Efficacy of GNR-097 Gene Therap… | Myopathies | Thérapie génique | Phase 1/2 | RECRUITING | The study will evaluate the tolerability, safety and efficacy of gene ther… À vérifier | ClinicalTrials.gov 2026-08-16 19:04:32 | Détail |
| PBGENE-DMD (IV) NCT07429240 · PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular… | Myopathies | À vérifier | Phase 1/2 | RECRUITING | The purpose of this Phase 1/2a trial is to evaluate the safety, tolerabili… À vérifier | ClinicalTrials.gov 2026-08-16 19:04:32 | Détail |
Découverte scientifique
Recherches et trouvailles 0
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune trouvaille ne correspond aux filtres. | |||||||
Bibliographie
Publications 585
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Botulinum Toxin Type A for the Treatment of Focal Spasticity in Child… Botulinum toxin type A · PMID 42461205 | Myopathies | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source Cerebral palsy (CP) causes lifelong functional impairment and societal burden. In Thailand, botulinum toxin type A (BoN… | Value in health regional issues 2026-07-18 15:47:41 | Source |
| Comparing the real-world effectiveness of botulinum toxin type A inje… Botulinum toxin type A · PMID 42465548 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source Post-stroke muscle hyper-resistance is produced by both neurogenic (spasticity) and non-neurogenic (contracture) factor… | Frontiers in neurology 2026-07-18 15:47:41 | Source |
| Individualized prediction of heroin cue-induced craving using task-ba… Intermittent theta burst stimulation · PMID 42469381 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Cue-induced craving is a core driver of addiction and relapse, and its significant heterogeneity represents a major bar… | NPJ digital medicine 2026-07-18 15:46:07 | Source |
| Intermittent theta burst stimulation modulates mirror visual feedback… Intermittent theta burst stimulation · PMID 42469892 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Theta burst stimulation (TBS) and mirror visual feedback (MVF) reduce interhemispheric asymmetry in both hemispheres, w… | Journal of neuroengineering and rehabilitation 2026-07-18 15:46:07 | Source |
| Alleviation effect of Potentilla anserina polysaccharides on intestin… Cyclophosphamide · PMID 42448191 | Myopathies | Immunomodulation | Publication | PubMed | Voir la publication source The present study aimed to analyze the physicochemical characteristics of Potentilla anserina polysaccharides (PAP) and… | International journal of biological macromolecules 2026-07-15 11:30:22 | Source |
| Real-world outcomes of BrECADD therapy in advanced-stage classical Ho… Cyclophosphamide · PMID 42448612 | Myopathies | Ralentissement de la progression · Thérapie génique | Publication | PubMed | Voir la publication source Advanced-stage classical Hodgkin lymphoma (cHL) has been traditionally treated with effective chemotherapy regimens, al… | British journal of haematology 2026-07-15 11:30:22 | Source |
| BAIBA attenuates pulmonary fibrosis by modulating the iron/ROS-mitoch… Metformin · PMID 42448057 | Myopathies | Remyélinisation indirecte / réparation · Neuroprotection | Publication | PubMed | Voir la publication source Pulmonary fibrosis (PF) is a chronic and progressive lung disease with limited therapeutic options. Beta-aminoisobutyri… | Free radical biology & medicine 2026-07-15 11:30:08 | Source |
| High Volume Hemofiltration : what are the last indications in 2026 -… Metformin · PMID 42447139 | Myopathies | Neuroprotection | Publication | PubMed | Voir la publication source High-dose continuous therapies and especially High-volume hemofiltration has failed to demonstrate clinical benefit in… | Blood purification 2026-07-15 11:30:08 | Source |
| Effect of 37°C Pre-Warmed Versus Room Temperature Gadoxetic Acid Diso… GenPHSat injection (Safety) · PMID 42446484 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Compromised patient comfort and suboptimal arterial phase (AP) image quality remain unresolved challenges in Gd-EOB-DTP… | Journal of magnetic resonance imaging : JMRI 2026-07-14 21:30:42 | Source |
| Safety and Efficacy of TrenibotulinumtoxinE for Moderate-to-Severe Gl… GenPHSat injection (Safety) · PMID 42446897 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Glabellar lines (GLs) are facial furrows that can become aesthetically displeasing because of aging and repetitive musc… | Aesthetic surgery journal 2026-07-14 21:30:42 | Source |
| From Control to Elimination: Making the End of Dental Caries Thinkabl… Behavioral Interventions for Controlling Oral Behaviors · PMID 42446275 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Dental caries remains one of the most prevalent noncommunicable diseases worldwide despite decades of clinical and beha… | Community dentistry and oral epidemiology 2026-07-14 21:30:34 | Source |
| Impact of anti-TNF and anti-IL-12/IL-23 antibody therapy on periodont… Behavioral Interventions for Controlling Oral Behaviors · PMID 42445195 | Myopathies | Immunomodulation | Publication | PubMed | Voir la publication source Periodontitis prevalence is elevated in patients with inflammatory bowel diseases (IBD). Biological therapies targeting… | Frontiers in immunology 2026-07-14 21:30:34 | Source |
| [Real-world testing of digital health: the INSPIRE Living Lab : An in… test of walk · PMID 42446712 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Digitalization in healthcare offers great potential for improving the quality of care and efficiency but often fails du… | Orthopadie (Heidelberg, Germany) 2026-07-14 21:30:22 | Source |
| Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/… Fludarabine · PMID 42446104 | Myopathies | Ralentissement de la progression · Thérapie cellulaire | Publication | PubMed | Voir la publication source To investigate the efficacy and safety of MTBF as conditioning regimen for salvage allogeneic hematopoietic stem cell t… | Cell transplantation 2026-07-14 21:30:10 | Source |
| Application Timing-Dependent Impact of Donor Source on Outcomes After… Cyclophosphamide · PMID 42446167 | Myopathies | Thérapie cellulaire · Thérapie génique | Publication | PubMed | Voir la publication source Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is usually performed as a curative treatment for adult T… | Hematological oncology 2026-07-14 21:30:08 | Source |
| Salvage ultra-low-dose radiotherapy for conjunctival mantle cell lymp… Cyclophosphamide · PMID 42445702 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with variable responses to frontline chemothera… | Reports of practical oncology and radiotherapy : journ… 2026-07-14 21:30:08 | Source |
| Evaluation of insulin, leptin, ghrelin, and adiponectin levels in typ… Metformin · PMID 42446258 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder, which is commonly related to reduced insulin responsiv… | Biomeditsinskaia khimiia 2026-07-14 21:29:33 | Source |
| Comparative Efficacy of Non-invasive Brain Stimulation for Pain, Anxi… Intermittent theta burst stimulation · PMID 42435147 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source Although non-invasive brain stimulation (NIBS) has been used to manage chronic musculoskeletal pain (CMP) and related e… | Pain and therapy 2026-07-14 21:29:07 | Source |
| Functional near-infrared spectroscopy study of intermittent theta bur… Intermittent theta burst stimulation · PMID 42440696 | Myopathies | Ralentissement de la progression | Publication | PubMed | Voir la publication source Stroke is characterized by high morbidity and high disability rate, and is the main cause of long-term disability. To e… | Frontiers in human neuroscience 2026-07-14 21:29:07 | Source |
| An Unusual Genetic Variant of Long QT Syndrome with Late Presentation… Mexiletine · PMID 42405015 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source This case report describes a 57-year-old woman with a history of transient loss of consciousness, initially treated as… | The Journal of innovations in cardiac rhythm management 2026-07-14 16:28:50 | Source |
Exploration — prudence
Pistes exploratoires 6
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| N-PPG N-PPG — modulation métabolique cérébrale | Myopathies | Remyélinisation indirecte / réparation · Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation métabolique et mitohormèse N-PPG est étudié dans Maladie de Huntington et documente plusieurs axes biologiques pouvant être pertinents pour Myopat… | Rapprochement Biomedical Watch · Maladie de Huntington | Détail |
| Vecteur Ple389 (ADORA2A) MiniPromoter Ple389 — ciblage striatal | Myopathies | Thérapie génique | Hypothèse exploratoire | Rapprochement automatique non validé | Expression génique ciblée dans les neurones striataux Vecteur Ple389 (ADORA2A) est étudié dans Maladie de Huntington et documente plusieurs axes biologiques pouvant être per… | Rapprochement Biomedical Watch · Maladie de Huntington | Détail |
| α-Amyrin α-Amyrin — protection mitochondriale | Myopathies | Remyélinisation indirecte / réparation · Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Protection mitochondriale et modulation de la pathologie Tau α-Amyrin est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pour Myopa… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Myopathies | Neuroprotection · Immunomodulation | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation immunométabolique de la microglie 4-octyl itaconate et dérivés est étudié dans Sclérose latérale amyotrophique et documente plusieurs axes biologiques po… | Rapprochement Biomedical Watch · Sclérose latérale amy… | Détail |
| Thonningianin A Thonningianin A — neuroprotection anti-amyloïde | Myopathies | Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Modulation du stress oxydatif et des protéines associées à Alzheimer Thonningianin A est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pou… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |
| Vutiglabridin Vutiglabridin — autophagie et PON2 | Myopathies | Neuroprotection | Hypothèse exploratoire | Rapprochement automatique non validé | Activation de PON2 et stimulation de l’autophagie Vutiglabridin est étudié dans Maladie d’Alzheimer et documente plusieurs axes biologiques pouvant être pertinents pour… | Rapprochement Biomedical Watch · Maladie d’Alzheimer | Détail |